SELECT showed CV benefit; what should patients monitor at home and what labs matter.
About this article
Reviewed byDr. Christian Bentley, M.D.
RoleCardiology Reviewer
First publishedMay 20, 2026
Last reviewedMay 20, 2026
Page typeIn-depth editorial guide
Sources15+ cited sources
BP changes on GLP-1
~3–5 mmHg systolic reduction is typical with significant weight loss. Patients on antihypertensives may need medication reduction. Home BP monitoring 2–3×/week through first 6 months recommended.
Lipid changes
LDL down 5–10%, triglycerides down 15–30%, HDL stable or slightly up. Repeat lipid panel at 3 and 6 months. Statin adjustment based on new lipid profile.
HR changes
~2–4 bpm increase in resting HR is common on GLP-1. Usually not clinically significant. New significant tachycardia warrants evaluation.
ECG considerations
No routine ECG indicated. New-onset arrhythmia (palpitations, sustained tachycardia) warrants evaluation.
When to coordinate with cardiology
- Established CVD on GLP-1 — coordinate with treating cardiologist.
- HFpEF + obesity — STEP-HFpEF supports continuation; cardiology coordination.
- Active atrial fibrillation, new chest pain, syncope — direct cardiology evaluation.